Targeting PCSK9 in clinical practice: Guidance & future

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam University Medical Centers, The Netherlands - Online CME

Video navigation menu

Issues surrounding lipid lowering therapy 1:10
Low-frequency injectable siRNA PCSK9 inhibition 4:55
Statin intolerance as major gap in ASCVD prevention 7:09
Other lipid targets to pursue 9:58

Educational information

This lecture by prof. John Kastelein was part of a CME accredited symposium: "PCSK9 inhibition: Science, outcomes and guidance" held at ESC 2018 in Munich, Germany.

Faculty

Prof. John Kastelein, MD – Professor of Medicine, Department of Vascular Medicine at the Amsterdam University Medical Centers (AUMC) of the University of Amsterdam, The Netherlands, where he holds the Strategic Chair of Genetics of Cardiovascular Disease

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.

Funding

Funding for this educational program was provided by an unrestricted educational grant from Amgen and Sanofi-Regeneron.

View slides of prof. Kastelein

Online-CME

This is available as accredited online CME for members. Click the button below to enroll:

Enroll

The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.